{"id":"W2752227448","doi":"10.1056/nejmoa1709030","title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2207,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Medical Research Council; Cancer Research UK","keywords":"Ipilimumab; Nivolumab; Medicine; Melanoma; Adjuvant; Adjuvant therapy; Oncology; Internal medicine; Placebo; Immunotherapy; Chemotherapy; Cancer; Cancer research; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001473913,0.0006143393,0.001712756,0.0002843452,0.0002321909,0.0005076934,0.0004559985,0.0005947761,0.002066283],"category_scores_gemma":[0.001768366,0.0003015665,0.001364241,0.0002030177,0.0004242888,0.0003558553,0.0002568492,0.00164053,0.0003092442],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007433989,"about_ca_system_score_gemma":0.001043184,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008117885,"about_ca_topic_score_gemma":0.001612446,"domain_scores_codex":[0.9994882,0.0002836933,0.00005537202,0.0000636179,0.00004484124,0.00006427089],"domain_scores_gemma":[0.9991672,0.0002998586,0.0001734524,0.00004296536,0.00003485299,0.000281715],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9273387,0.00553244,0.003168524,0.0005761403,0.0009142619,0.00006870637,0.00006832361,0.001442543,0.0057706,0.00007757105,0.0005400695,0.05450215],"study_design_scores_gemma":[0.525883,0.4437955,0.0186043,0.0002232401,0.001681681,0.0002609348,0.00006689094,0.003388907,0.003793669,0.0004279182,0.001842728,0.00003122657],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938591,0.004370653,0.0002830582,0.0001939231,0.0001999304,0.000433887,0.0001144138,0.00002362644,0.0005213511],"genre_scores_gemma":[0.9965984,0.001778668,0.0004013922,0.0002312449,0.0001426015,0.000291602,0.0001445033,0.000004963545,0.0004066198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002066283,"threshold_uncertainty_score":0.007794917,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05226193040225233,"score_gpt":0.3429099879807146,"score_spread":0.2906480575784622,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}